Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ming Xu
University of Connecticut Sch of Med/dnt, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Unity Biotechnology
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Dr Wu is one of the inventors of an IP developed at the (b)(4) for a senolytic cocktail that it would be use in this research.
The IP has not generated any royalties yet, but it has being licensed to Unity Biotechnology, Dr Xu received the stock as part of the licensing agreement.
Role of Senolytics in Lower Urinary Tract Aging and Voiding Disorders
Project Narrative Lower Urinary Tract Symptoms including urinary incontinence, frequency, urgency and nocturia are widely prevalent in older individuals, with incontinence being one of the most common reasons for nursing home admissions. These symptoms often lead to isolation and depression in older adults. Thus far, drugs targeting bladders for treatment of urinary control problems are not particularly effective, and are often abandoned due to undesirable side effects. Bladder control is a very complex operation and requires functioning communication between the brain and bladder as well as a healthy bladder. Given the role of aging in these conditions, we will test for the first time how drugs that target aging biological pathways throughout the body might result in preventing or curing bladder dysfunction in an aged mouse model. Our findings could lead to the development of a whole new category of medications for the prevention and treatment of voiding disorders and incontinence in old age.
Filed on April 16, 2019.
Tell us what you know about Ming Xu's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.